echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Alpha-fetoprotein as a prognostic biomarker for hepatocellular carcinoma treated with Atezolizuma+bevacizumab

    Clin Cancer Res: Alpha-fetoprotein as a prognostic biomarker for hepatocellular carcinoma treated with Atezolizuma+bevacizumab

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alpha-fetoprotein (AFP) is the most widely detected serum tumor marker for hepatocellular carcinoma (HCC), and AFP overexpression is thought to be a reflection of more aggressive tumor biology and burden


    Atezolizuma+bevacizumab is the new standard of care for systemic-naïve, unresectable hepatocellular carcinoma (HCC)


    The researchers used the data from the Phase Ib GO30140 study arm A to determine the optimal time to detect AFP and the cut-off value to distinguish different treatment responses in patients




    A ≥75% decrease in AFP at 6 weeks of treatment was used as the cutoff to identify responders, and an AFP increase of ≤10% was used as the cutoff to identify patients with disease control Both AFP cutoffs were associated with longer overall survival and progression-free survival Both AFP cutoffs were associated with longer overall and progression-free survival



    AFP response at week 6 of initiation of therapy as a surrogate biomarker of prognosis in patients with hepatocellular carcinoma receiving Atezolizuma + bevacizumab Surrogate biomarkers for prognosis in cancer patients

    Original source:

    Original source:

    Andrew X.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.